Your browser doesn't support javascript.
loading
Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food-A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper.
Zuberbier, Torsten; Dörr, Tamara; Aberer, Werner; Alvaro, Montserrat; Angier, Elizabeth; Arasi, Stefania; Arshad, Hasan; Ballmer-Weber, Barbara; Bartra, Joan; Beck, Lisa; Bégin, Philippe; Bindslev-Jensen, Carsten; Bislimovska, Jovanka; Bousquet, Jean; Brockow, Knut; Bush, Andrew; Cianferoni, Antonella; Cork, Michael J; Custovic, Adnan; Darsow, Ulf; de Jong, Nicolette; Deleanu, Diana; Del Giacco, Stefano; Deschildre, Antoine; Dunn Galvin, Audrey; Ebisawa, Motohiro; Fernández-Rivas, Montserrat; Ferrer, Marta; Fiocchi, Alessandro; Gerth van Wijk, Roy; Gotua, Maia; Grimshaw, Kate; Grünhagen, Josefine; Heffler, Enrico; Hide, Michihiro; Hoffmann-Sommergruber, Karin; Incorvaia, Cristoforo; Janson, Christer; Malte John, Swen; Jones, Carla; Jutel, Marek; Katoh, Norito; Kendziora, Benjamin; Kinaciyan, Tamar; Knol, Edward; Kurbacheva, Oksana; Lau, Susanne; Loh, Richard; Lombardi, Carlo; Mäkelä, Mika.
Afiliação
  • Zuberbier T; Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Humboldt-Uniersität zu Berlin and Berlin Institute of Health, Comprehensive Allergy-Centre, Berlin, Germany.
  • Dörr T; Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Humboldt-Uniersität zu Berlin and Berlin Institute of Health, Comprehensive Allergy-Centre, Berlin, Germany.
  • Aberer W; Department of Dermatology, Medical University of Graz, Graz, Austria.
  • Alvaro M; Servei Al-lergologia Immunologia Clinica, Hospital Sant Joan de Deu, Barcelona, Spain.
  • Angier E; Primary Care, Population Science and Medical Education, Faculty of Medicine, University of Southampton, Southampton, UK.
  • Arasi S; Pediatric Allergology Unit, Bambino Gesù Hospital (IRCCS), Rome, Italy.
  • Arshad H; NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
  • Ballmer-Weber B; Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
  • Bartra J; The David Hide Asthma and Allergy Research Centre, St Mary's Hospital, Isle of Wight, UK.
  • Beck L; Department of Dermatology, University Hospital Zürich, Zürich, Switzerland.
  • Bégin P; Clinic for Dermatology and Allergology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
  • Bindslev-Jensen C; Unitat d'Al.lergia, Servei de Neumologia i Al.lergia Respiratoria, Hospital Clinic, Barcelona, Spain.
  • Bislimovska J; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Bousquet J; Department of Dermatology, University of Rochester Medical Center, Rochester, New York, USA.
  • Brockow K; CHU Sainte-Justine, Montréal, Canada.
  • Bush A; Department of Dermatology and Allergy Center, Odense Research Centre for Anaphylaxis (ORCA), Odense University Hospital Denmark, Odense, Denmark.
  • Cianferoni A; Faculty of Medicine, Ss. Cyril and Methodius, University in Skopje, Institute of Occupational Health of RNM, WHO Collaborating Center, Skopje, Macedonia.
  • Cork MJ; Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Humboldt-Uniersität zu Berlin and Berlin Institute of Health, Comprehensive Allergy-Centre, Berlin, Germany.
  • Custovic A; University Hospital Montpellier, Montpellier, France.
  • Darsow U; MACVIA-France, Montpellier, France.
  • de Jong N; Department of Dermatology and Allergy Biederstein, School of Medicine, Technical University of Munich, Munich, Germany.
  • Deleanu D; Imperial College and Royal Brompton Hospital, London, UK.
  • Del Giacco S; Department of Pediatrics, University of Pennsylvania, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Deschildre A; University of Sheffield, Sheffield, UK.
  • Dunn Galvin A; National Heart and Lung Institute, Imperial College London, London, UK.
  • Ebisawa M; Department of Dermatology and Allergy Biederstein, School of Medicine, Technical University of Munich, Munich, Germany.
  • Fernández-Rivas M; Section of Allergology and Clinical Immunology, Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands.
  • Ferrer M; University Medicine and Pharmacy Iuliu Hatieganu, IRGH, Allergy, Cluj-Napoca, Romania.
  • Fiocchi A; Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
  • Gerth van Wijk R; CHU Lille, Univ Lille, Lille, France.
  • Gotua M; Pediatric Pulmonology and Allergy Unit, Hôpital Jeanne de Flandre, Lille, France.
  • Grimshaw K; University College Cork, Cork, Ireland.
  • Grünhagen J; Sechenov University Moscow, Moscow, Russia.
  • Heffler E; Anaphylaxis Ireland, Cork, Ireland.
  • Hide M; Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, Japan.
  • Hoffmann-Sommergruber K; Allergy Department, Facultad de Medicina, Hospital Clínico San Carlos, Universidad Complutense (UCM), IdISSC, Madrid, Spain.
  • Incorvaia C; Department of Allergy, Clinica Universidad de Navarra, Pamplona, Spain.
  • Janson C; Pediatric Allergology Unit, Bambino Gesù Hospital (IRCCS), Rome, Italy.
  • Malte John S; Section of Allergology and Clinical Immunology, Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands.
  • Jones C; Center of Allergy and Immunology, Tbilisi, Georgia.
  • Jutel M; Dietetic Department, Salford Care Organisation, Salford Royal Foundation Trust, Salford, UK.
  • Katoh N; Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Humboldt-Uniersität zu Berlin and Berlin Institute of Health, Comprehensive Allergy-Centre, Berlin, Germany.
  • Kendziora B; Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Research Hospital, Rozzano (MI), Italy.
  • Kinaciyan T; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy.
  • Knol E; Department of Dermatology, Hiroshima Citizens Hospital, Hiroshima, Japan.
  • Kurbacheva O; Department of Pathophysiology and Allergy Research, Medical University of Vienna, Austria.
  • Lau S; Cardiac/Pulmonary Rehabilitation, ASST Pini/CTO, Milan, Italy.
  • Loh R; Department of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden.
  • Lombardi C; Department of Dermatology, Environmental Medicine, Health Theory, University of Osnabrueck, Osnabrueck, Germany.
  • Mäkelä M; Institute for Interdisciplinary Dermatological Prevention and Rehabilitation (iDerm) at the University of Osnabrueck, Osnabrueck, Germany.
Allergy ; 77(6): 1736-1750, 2022 06.
Article em En | MEDLINE | ID: mdl-34741557
BACKGROUND: Food anaphylaxis is commonly elicited by unintentional ingestion of foods containing the allergen above the tolerance threshold level of the individual. While labeling the 14 main allergens used as ingredients in food products is mandatory in the EU, there is no legal definition of declaring potential contaminants. Precautionary allergen labeling such as "may contain traces of" is often used. However, this is unsatisfactory for consumers as they get no information if the contamination is below their personal threshold. In discussions with the food industry and technologists, it was suggested to use a voluntary declaration indicating that all declared contaminants are below a threshold of 0.5 mg protein per 100 g of food. This concentration is known to be below the threshold of most patients, and it can be technically guaranteed in most food production. However, it was also important to assess that in case of accidental ingestion of contaminants below this threshold by highly allergic patients, no fatal anaphylactic reaction could occur. Therefore, we performed a systematic review to assess whether a fatal reaction to 5mg of protein or less has been reported, assuming that a maximum portion size of 1kg of a processed food exceeds any meal and thus gives a sufficient safety margin. METHODS: MEDLINE and EMBASE were searched until 24 January 2021 for provocation studies and case reports in which one of the 14 major food allergens was reported to elicit fatal or life-threatening anaphylactic reactions and assessed if these occurred below the ingestion of 5mg of protein. A Delphi process was performed to obtain an expert consensus on the results. RESULTS: In the 210 studies included, in our search, no reports of fatal anaphylactic reactions reported below 5 mg protein ingested were identified. However, in provocation studies and case reports, severe reactions below 5 mg were reported for the following allergens: eggs, fish, lupin, milk, nuts, peanuts, soy, and sesame seeds. CONCLUSION: Based on the literature studied for this review, it can be stated that cross-contamination of the 14 major food allergens below 0.5 mg/100 g is likely not to endanger most food allergic patients when a standard portion of food is consumed. We propose to use the statement "this product contains the named allergens in the list of ingredients, it may contain traces of other contaminations (to be named, e.g. nut) at concentrations less than 0.5 mg per 100 g of this product" for a voluntary declaration on processed food packages. This level of avoidance of cross-contaminations can be achieved technically for most processed foods, and the statement would be a clear and helpful message to the consumers. However, it is clearly acknowledged that a voluntary declaration is only a first step to a legally binding solution. For this, further research on threshold levels is encouraged.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hipersensibilidade Alimentar / Anafilaxia Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hipersensibilidade Alimentar / Anafilaxia Idioma: En Ano de publicação: 2022 Tipo de documento: Article